Biotech's Lookin' Good (for a bit at least)Bull flag that looked for a short while like it was pulling a head-fake and retreating but in the last hour of trading (as always) my instincts are rewarded and it continues to climb up. I've put in a prospective overhead resistance but remember to trail your stops because anything can happen! Other ETF's are looking bullish too like DRN, SOXL and TECL.
Biotechnology
Trevena, Inc. (TRVN) short.All description on the chart.
Please, don't forget to like and follow.
Thank you.
Bluebird Bio (BLUE) short.All description on the chart.
Please, don't forget to like and follow.
Thank you.
PARADIGM - 160% PROFIT TO CONTINUEPay close attention to PARADIGM (PAR). 3 Potential Moves
1. We bounce off the .382 Fib level and return to test the 2.80 mark which we saw on 11/05/20
-Being the end of the trading week I suspect the latter.
2. We break the .382 Fib level and Uptrend and head for the 'Golden Pocket'
-Bounce off strong support at 2.00 mark
-MACD is starting to squeeze but if we find momentum next week we could start to spread again.
-PAR loves the .5 Fibonacci Retracement level. (Short term fact)
-We hit the deeper uptrend and continue back up towards the 2.80 mark to test a strong EQ Resistance Level. Very Possible
-It regains buyer momentum in the 'Golden Pocket' between the .5-.618 Fib Level. Very Possible
-Positive news released early next week bring strong buying sentiment back into the market and create an Higher Low ready for the next leg up.
3. We BREAK both uptrend trendlines creating NEW Bearish Market Structure and head for the next Major Support @ 1.48
Another company im keeping a close eye on. PARADIGM BIOPHARMACEUTICALS LTD is a late stage drug development company with their aim to treat musculoskeletal disorders in humans with degenerative disease driven by injury, viral infection, aging or genetic predisposition.
They have a cash balance sheet of $108 Million (06/04/20), FDA Approval, IP Protection & Patents, Agreements that stand for 20 years regarding manufacturing, Fully funded until 2022. EYES ON!!!
These Ideas are NOT 'Financial Advice'!. Scenarios are based off a mixture of TA and Fundamentals current at the time. All IMO GLTAH. Happy Hunting!!!
MRNA was a top gainer,rising 106.32%.Expect Uptrend continuationModerna (MRNA, $62) was one of top quarterly gainers, jumping +106.32% to $62 per share. Tickeron A.I.dvisor analyzed 380 stocks in the Biotechnology Industry over the last three months, and discovered that 357 of them (94.07%) charted an Uptrend while 23 of them (5.93%) trended down. Tickeron A.I.dvisor found 135 similar cases when MRNA's price jumped over 15% within three months. In 84 out of those 135 cases, MRNA's price went up during the following month. Based on these historical data, Tickeron A.I. thinks the odds of an Uptrend continuation for MRNA are 62%.
Wall Street is Short VBIV, but I'm Long *Target: [$3.50]*Link to Culper Research report that states they are shorting VBIV because the company is "worthless"
img1.wsimg.com
First, it's always important to consider ALL information. It's also important to be transparent about knowledge. If you are going to make any VBIV trades you really should read the entire report.
1) I think many of the points made in the Culper Report are legitimate
2) I am not as optimistic about long term price targets as those seen at Guggenheim and on yahoo finance
3) I still believe this is a good short-term trade based on sentiment and momentum regarding June 22-24 release of clinical glioblastoma data
Stop loss @ $2.04
AVRO 50-day MA moved above its 200-day MA on June 24, 2020Tickeron AI shows that a buy signal is indicated by this change in price, due to the trend repositioning higher. In 2 of 2 cases where AVRO's 50-day Moving Average crossed above its 200-day Moving Average, its price rose further within the subsequent month. The odds of a continued Uptrend are 90%.
Novavax (NVAX) stock price is on track...for now [LONG]Just re-iterating my previous assertion (guess) that NVAX is on course for massive gains in the long-term. Doesn't mean it's a great company but this pandemic has initiated a similar pattern in the past. They have several great developments in the works: NanoFlu, RSV F, and a COVID-19 vaccine candidate. See my previous posts especially the related one.
This is purely speculation based on their pipeline. This is not financial advice.
PFNX Aroon Indicator entered an Uptrend on June 23, 2020.Over the last three days, Tickeron AI has detected that PFNX's AroonUp green line (see chart) is above 70, while the AroonDown red line is below 30. When the green line goes above 70 while the red line stays below 30, this is an indicator that the stock could be poised for a strong Uptrend. For traders, this could mean going long the stock or exploring call options in the next month. Tickeron A.I.dvisor backtested this indicator and found 150 similar cases, 135 of which were successful. Based on this data, the odds of success are 90%.
FPRX was a top gainer,rising +132.36%.Expect an Uptrend reversalFive Prime Therapeutics (FPRX, $6.39) was one of top quarterly gainers, jumping +132.36% to $6.39 per share. Tickeron A.I.dvisor analyzed 380 stocks in the Biotechnology Industry over the last three months, and discovered that 356 of them (93.72%) charted an Uptrend while 24 of them (6.28%) trended down. Tickeron A.I.dvisor found 279 similar cases when FPRX's price went up 15% within three months. In 201 out of those 279 cases, FPRX's price went down during the following month. Based on these historical data, Tickeron A.I. thinks the odds of an Uptrend reversal for FPRX are 72%.
KURA MA MACD Histogram just turned positiveThis is a Bullish indicator signaling KURA's price could rise from here. Traders may explore going long the stock or buying call options. I identified 47 similar cases where KURA's MACD histogram became positive, and 39 of them led to successful outcomes. Odds of Success: 83%.
IONS MA MACD Histogram just turned positiveThis is a Bullish indicator signaling IONS's price could rise from here. Traders may explore going long the stock or buying call options. I identified 40 similar cases where IONS's MACD histogram became positive, and 35 of them led to successful outcomes. Odds of Success: 88%.
KURA MACD Histogram just turned positiveThis is a Bullish indicator signaling KURA's price could rise from here. Traders may explore going long the stock or buying call options. I identified 47 similar cases where KURA's MACD histogram became positive, and 39 of them led to successful outcomes. Odds of Success: 83%.
CBAY enters Uptrend as Momentum indicator ascends above 0 levelThis indicator may be signaling that CBAY's price has momentum to move higher, since its current price exceeds the price logged 14 days ago. Traders may consider buying the stock or exploring call options. I backtested 91 similar cases where CBAY's Momentum Indicator exceeded 0, and 78 of them led to a successful outcome. Odds of Success: 86%.
Biotech Looking a Little Sick: LABDAnother descending triangle has appeared in LABD. My numerous other finds have yielded decent results but we have yet to see a turn in the market indicating a new direction. The play itself might be worth a couple of percent gain but please trade safely. The downturn near the end of Friday's session is forecasting a likely poor Monday opening in addition to the negative news that continues to come out of the ECB and New York.
ACAD MA MACD Histogram just turned positiveA buy signal is generated. This is a Bullish indicator signaling ACAD's price could rise from here. Traders may explore going long the stock or buying call options. I identified 45 similar cases where ACAD's MACD histogram became positive, and 38 of them led to successful outcomes. Odds of Success: 84%.
Merck has upside to $82Analyst forecasts for Merck earnings came down sharply early this year, but lately they've stabilized and even ticked upward a little. Merck is still priced for an optimistic market, with forward P/E around 15 and PEG around 2-3. This is reasonable for a large cap company with 3% dividend and a great reputation, but it's not bargain pricing, exactly. A second round of lockdowns or a second wave of Covid-19 could hurt the stock again.
But as long there's no major deterioration of the macroeconomic outlook, the fair value range for Merck is about $75-82 per share. Analysts have been slow to make any forecasts for 2022 due to macroeconomic uncertainty, but I predict that the top end of the fair value range will shift upward to $87 per share once the 2022 forecasts finally come in.
Merck is oversold today on the hourly RSI and curling upward. MACD is below the signal line, but also curling upward. A few minutes ago Merck announced an FDA approval to expand the label for GARDASIL, its HPV drug. I suspect this may function as a catalyst to send Merck back upward toward $82 per share. I bought some shares after-hours, and if I can get in cheap enough, I will consider some call options tomorrow with maybe a one-month expiration.
NOVNNOVN sitting right below 50 ema and above POC 100 ema around .64 & VPVR is non existant above .77c